Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Malignant Salivary Tumors.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Dasatinib (Primary)
- Indications Adenocarcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Nov 2015 Results published in the Annals of Oncology
- 12 Dec 2012 Planned end date changed from 1 Aug 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.